Corus Entertainmt B (CJREF) 10.0199 $CJREF Corus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Corus Entertainmt B (CJREF) 10.0199 $CJREF

Corus Entertainment Has Returned 29.2% Since SmarTrend Recommendation (CJREF)
Comtex SmarTrend(R) - Wed Aug 10, 1:40PM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 5 months, Corus Entertainment has returned 29.19% as of today's recent price of $10.02.

Uptrend Call Working As Corus Entertainment Stock Rises 25.7% (CJREF)
Comtex SmarTrend(R) - Wed Aug 03, 1:15AM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 5 months, Corus Entertainment has returned 25.70% as of today's recent price of $9.75.

Corus Entertainment Shares Up 34.0% Since SmarTrend's Buy Recommendation (CJREF)
Comtex SmarTrend(R) - Fri Jun 24, 12:42AM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 4 months, Corus Entertainment has returned 33.98% as of today's recent price of $10.39.

Corus Entertainment Shares Up 25.3% Since SmarTrend's Buy Recommendation (CJREF)
Comtex SmarTrend(R) - Wed Jun 01, 1:27PM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 3 months, Corus Entertainment has returned 25.34% as of today's recent price of $9.72.

Corus Entertainment Up 20.6% Since SmarTrend Uptrend Call (CJREF)
Comtex SmarTrend(R) - Wed May 25, 1:07AM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 3 months, Corus Entertainment has returned 20.57% as of today's recent price of $9.35.

Shares of CJREF Up 21.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 12, 1:56PM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 1 month, Corus Entertainment has returned 20.95% as of today's recent price of $9.38.

Uptrend Call Working As Corus Entertainment Stock Rises 19.5% (CJREF)
Comtex SmarTrend(R) - Mon Apr 04, 1:09PM CDT
SmarTrend identified an Uptrend for Corus Entertainment (NASDAQ:CJREF) on February 29th, 2016 at $7.76. In approximately 1 month, Corus Entertainment has returned 19.54% as of today's recent price of $9.27.

16.9% Return Seen to Date on SmarTrend Corus Entertainment Call (CJREF)
Comtex SmarTrend(R) - Tue Jan 05, 6:38PM CST
SmarTrend identified a Downtrend for Corus Entertainment (NASDAQ:CJREF) on October 22nd, 2015 at $9.53. In approximately 3 months, Corus Entertainment has returned 16.89% as of today's recent price of $7.92.

22.6% Return Seen to Date on SmarTrend Corus Entertainment Call (CJREF)
Comtex SmarTrend(R) - Tue Dec 22, 1:44PM CST
SmarTrend identified a Downtrend for Corus Entertainment (NASDAQ:CJREF) on October 22nd, 2015 at $9.53. In approximately 2 months, Corus Entertainment has returned 22.56% as of today's recent price of $7.38.

Corus Entertainment Shares Down 27.2% Since SmarTrend's Sell Call (CJREF)
Comtex SmarTrend(R) - Tue Dec 15, 10:05AM CST
SmarTrend identified a Downtrend for Corus Entertainment (NASDAQ:CJREF) on October 22nd, 2015 at $9.53. In approximately 2 months, Corus Entertainment has returned 27.18% as of today's recent price of $6.94.

Shares of CJREF Down 22.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 08, 9:44AM CST
SmarTrend identified a Downtrend for Corus Entertainment (NASDAQ:CJREF) on October 22nd, 2015 at $9.53. In approximately 2 months, Corus Entertainment has returned 22.36% as of today's recent price of $7.40.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading